Keenova Therapeutics plc·4

Jun 4, 4:12 PM ET

Dorton Katina 4

4 · Keenova Therapeutics plc · Filed Jun 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Keenova Director Dorton Katina Receives 4,882 Shares (RSU Settlement)

What Happened

  • Director Dorton Katina had 4,882 restricted stock units (RSUs) settle into 4,882 ordinary shares on June 2, 2026. The filing also reports a simultaneous disposal of 4,882 shares at $0.00, resulting in no cash proceeds reported. The Form 4 uses transaction code M (exercise/conversion of a derivative) to reflect the settlement/conversion.

Key Details

  • Transaction date: 2026-06-02; Form 4 filed: 2026-06-04 (timely filing).
  • Acquired: 4,882 shares via RSU settlement (price N/A per share). Disposed: 4,882 shares at $0.00 (no cash proceeds reported).
  • Shares owned after transaction: not specified in the provided excerpt.
  • Footnotes: F1 — each RSU settled into one ordinary share; F2 — RSUs were granted Aug 14, 2025 and vest on the earlier of the first anniversary of the grant or the issuer’s next annual general meeting.
  • Transaction code: M = exercise/conversion of derivative (here, RSU settlement).

Context

  • This was an RSU settlement (award conversion), not an open-market purchase or sale. The simultaneous $0.00 disposition is commonly used to reflect shares withheld or converted to satisfy tax or similar obligations on settlement; the filing shows no cash proceeds. Such award settlements are routine and do not necessarily indicate a change in insider sentiment.

Insider Transaction Report

Form 4
Period: 2026-06-02
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-06-02+4,8827,387 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F2]
    2026-06-024,88227,000 total
    Ordinary Shares (4,882 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
  • [F2]The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
Signature
/s/ Mark Tyndall, Attorney-in-Fact|2026-06-04

Documents

1 file
  • 4
    tm2616870-5_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT